What are the side effects of osimertinib?

Osimertinib (Tagrisso) As a third-generation irreversibleEGFR-TKI (epidermal growth factor receptor tyrosine kinase inhibitor), it has demonstrated significant clinical activity in the treatment of non-small cell lung cancer (NSCLC). It is particularly worth mentioning that it also has an antagonistic effect on metastatic lesions in the central nervous system (CNS). This characteristic makes osimertinib occupy a unique position in the treatment of NSCLC.

Get emergency medical help if a patient taking osimertinib has signs of an allergic reaction (hives, difficulty breathing, swelling of the face or throat) or a severe skin reaction (fever, sore throat, burning eyes, skin pain, peeling, red or purple rash with blisters and swelling).

Osimertinib may cause serious side effects. Contact your doctor immediately if you have: red or purple spots on your skin that do not turn white when you press them,24 Redness or bruising that persists after hours (may appear on the arms, legs, buttocks, or abdomen); redness, rash, or blisters on the palms or soles of the feet; new or worsening cough or difficulty breathing; fast or pounding heartbeat; swelling of the lower legs, weight gain, shortness of breath; feeling of dizziness, Like you might pass out; low blood count - fever, chills, tiredness, mouth sores, skin sores, easy bruising, unusual bleeding, pale skin, cold hands and feet; or eye problems - vision changes, watering, increased light sensitivity, eye pain or redness. If you experience certain side effects, your cancer treatment may be delayed or permanently stopped.

Common side effects of osimertinib may include: low blood counts; muscle, bone, or joint pain; diarrhea; fatigue; cough, mouth sores; dry skin, rash; or redness, tenderness, pain, or other problems with your fingernails or toenails. This is not a complete list of side effects, and other side effects may occur. If you experience any discomfort while taking osimertinib, you should consult your doctor immediately.

In short, osimertinib is a third-generation EGFR-targeted drug that has a significant therapeutic effect in non-small cell lung cancer. Patients should consult a professional doctor before using the medicine and use the medicine under the guidance of a doctor.